Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease.
about
To Extinguish the Fire from Outside the Cell or to Shutdown the Gas Valve Inside? Novel Trends in Anti-Inflammatory TherapiesBeyond the NLRP3 inflammasome: autoinflammatory diseases reach adolescenceChronic Infantile Neurological Cutaneous and Articular (CINCA) syndrome: a reviewThe PYRIN domain in signal transductionCOPs and POPs: modulators of inflammasome activityPotential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases.Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes: finding the right balance in response to danger signalsThe serum and cerebrospinal fluid pharmacokinetics of anakinra after intravenous administration to non-human primates.Follistatin-like protein 1 is a mesenchyme-derived inflammatory protein and may represent a biomarker for systemic-onset juvenile rheumatoid arthritis.Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition.The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivoPharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat).Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectivesAn expanding role for interleukin-1 blockade from gout to cancer.Adipokines as drug targets in diabetes and underlying disturbances.Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.The anesthetic management of children with neonatal-onset multi-system inflammatory diseaseBlocking IL-1 in systemic inflammationUpdated consensus statement on biological agents for the treatment of rheumatic diseases, 2007Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade.CATERPILLERs, pyrin and hereditary immunological disorders.P2 purinergic receptor modulation of cytokine production.The Central Role of Anti-IL-1 Blockade in the Treatment of Monogenic and Multi-Factorial Autoinflammatory Diseases.NOD-like receptors and inflammation.Treating inflammation by blocking interleukin-1 in humans.DEK-targeting DNA aptamers as therapeutics for inflammatory arthritis.Biologics in children's autoimmune disorders: efficacy and safety.Treatment for radiation-induced pulmonary late effects: spoiled for choice or looking in the wrong direction?Anakinra for cryopyrin-associated periodic syndrome.Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome.Equine performance genes and the future of doping in horseracing.The burgeoning field of innate immune-mediated disease and autoinflammation.Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome.Anakinra and related drugs targeting interleukin-1 in the treatment of cryopyrin-associated periodic syndromes.XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases.Cochlear implantation in a child with CINCA syndrome who also has wide vestibular aqueducts.Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS).A case report of neonatal onset multisystemic inflammatory disease in Japan treated with continuous hemodiafiltration and steroid pulse therapy.Anakinra in the treatment of rheumatic disease.
P2860
Q26786973-7A614819-4CD9-4303-B78F-4B21F07A8D89Q27011650-CB2B3E7F-1DCB-492E-877E-FFFDA82D028FQ28066948-6B8670B3-45EC-4F48-8907-9A978B99AA09Q28383855-44D4D2DB-967D-43E5-86C2-1417F82C857DQ28387485-8FDFF7BA-E0C0-41C5-80E6-53B01EED82C0Q33710807-C9B42502-F913-417C-8045-AB8244BFB2DDQ33798590-7AEC17F7-25B8-4750-9DA4-C4FC263E656CQ33920739-A6B4D3F2-2395-46F6-BF4B-182566DAB18EQ34063418-394C68DD-74FC-4E2E-BA0B-A85C96844EB3Q34262569-DEBAD933-30C3-4C55-B095-4C5A32EA14D4Q34504770-BE688395-AC82-4891-96CF-48C2EC67BCEBQ35016969-3A781127-71E4-4D59-B999-56FD8198EDADQ35133812-DC2B3702-372E-4D5B-A3D9-0B42800B01C0Q35219001-21B40231-8F6B-4CE3-8FB4-41CC46A6067DQ35415815-A53FF34E-DBCF-495D-8123-A00B1097D993Q35579517-33BE2C9A-D3F0-47DF-BF52-62117505F558Q35638252-92593F04-66B3-4DDC-9DA4-B9E2FE6D4BA5Q36050284-DFA4730F-D35C-4E59-87F5-1A413B28E41FQ36113777-2EAFCCE7-F20B-4C38-8CEF-4F2C22876814Q36171750-9E29C1D8-ABC8-4469-B866-5ACBCC1EC2EDQ36229664-47DD6EE5-01F5-416E-8FB8-E71A3E1B4953Q36405072-03424B75-1631-4F2B-9260-52630108D50FQ37135491-E01868A4-5EF6-4C09-8ECB-BF4647F2CBB7Q37270409-D6E80FE4-5E9A-47A8-BB77-AC828C58D59FQ37353179-84778EF8-E456-40CE-A8F7-CFCBCDA3F4F9Q37636664-980AD816-18E1-4E8E-BBE9-75C0F40BFC13Q37637728-F476A761-50E5-4716-AC9C-3455AE17D365Q37765830-A1FFBCD9-9352-4584-B1F2-91C652A2F047Q37768188-60184EA0-8967-4E91-8C94-D86111C57C6EQ38168948-7D9DEBD2-D2A2-4594-8251-A21E93F28EEDQ38574807-8DB9B135-5F30-4E61-9DB4-22B6FD4D255FQ38738678-70BE7BF8-1076-4A83-A6C7-24DAAD3BFC3FQ38967233-BDDB74BC-FEA6-4B92-B79C-8CF8B67A4947Q38993264-66D221C6-C14E-4686-A9F7-EB7DED1B68B4Q38993312-8B0445FB-32A6-4DB8-9C68-0D9053068B7EQ39635974-10146D3D-EFAE-48EA-9F05-66BB24709B5FQ40296372-DD7A8473-05F6-460D-BEB2-1B6FA123ADA3Q40356964-681E69E4-1F04-4B0A-88D0-F04C5256935BQ40450062-DDDF8A4A-9A49-4330-AAFF-DAFE8F691E79Q43061720-96B4FA76-F76F-4359-852E-86DE5302C91D
P2860
Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease.
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Interleukin-1 blockade by anak ...... tisystem inflammatory disease.
@ast
Interleukin-1 blockade by anak ...... tisystem inflammatory disease.
@en
type
label
Interleukin-1 blockade by anak ...... tisystem inflammatory disease.
@ast
Interleukin-1 blockade by anak ...... tisystem inflammatory disease.
@en
prefLabel
Interleukin-1 blockade by anak ...... tisystem inflammatory disease.
@ast
Interleukin-1 blockade by anak ...... tisystem inflammatory disease.
@en
P2093
P356
P1476
Interleukin-1 blockade by anak ...... tisystem inflammatory disease.
@en
P2093
Alan M Solinger
Daniel J Lovell
Suzanne L Bowyer
P304
P356
10.1002/ART.20953
P577
2005-04-01T00:00:00Z